HBK Sorce Advisory LLC boosted its holdings in shares of Eli Lilly and Co (NYSE:LLY) by 45.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 21,793 shares of the company’s stock after buying an additional 6,840 shares during the quarter. HBK Sorce Advisory LLC’s holdings in Eli Lilly and were worth $1,841,000 at the end of the most recent reporting period.
Other institutional investors have also recently bought and sold shares of the company. Gradient Investments LLC bought a new stake in shares of Eli Lilly and in the fourth quarter valued at approximately $103,000. Avestar Capital LLC bought a new stake in Eli Lilly and during the fourth quarter worth $100,000. MPS Loria Financial Planners LLC bought a new stake in Eli Lilly and during the second quarter worth $128,000. San Francisco Sentry Investment Group CA bought a new stake in Eli Lilly and during the second quarter worth $129,000. Finally, Willingdon Wealth Management bought a new stake in Eli Lilly and during the third quarter worth $138,000. 77.63% of the stock is currently owned by institutional investors.
Several equities research analysts have weighed in on the company. BMO Capital Markets restated a “sell” rating and set a $74.00 target price on shares of Eli Lilly and in a research note on Wednesday. Credit Suisse Group reiterated a “hold” rating and issued a $80.00 price target on shares of Eli Lilly and in a research note on Friday, February 2nd. TheStreet downgraded Eli Lilly and from a “b” rating to a “c” rating in a report on Monday, March 5th. Argus upgraded Eli Lilly and from a “hold” rating to a “buy” rating and increased their price objective for the company from $85.52 to $115.00 in a report on Friday, January 5th. Finally, Zacks Investment Research downgraded Eli Lilly and from a “buy” rating to a “hold” rating in a report on Tuesday, March 27th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have assigned a buy rating to the stock. Eli Lilly and has an average rating of “Hold” and an average target price of $92.84.
Shares of LLY stock opened at $76.85 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.32 and a debt-to-equity ratio of 0.85. Eli Lilly and Co has a 12-month low of $73.69 and a 12-month high of $89.09. The company has a market cap of $86,135.91, a PE ratio of 17.96, a P/E/G ratio of 1.43 and a beta of 0.26.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.06. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 33.01%. The business had revenue of $6.16 billion during the quarter, compared to analyst estimates of $5.93 billion. During the same period in the previous year, the business earned $0.95 EPS. Eli Lilly and’s revenue was up 7.0% compared to the same quarter last year. equities analysts forecast that Eli Lilly and Co will post 4.87 earnings per share for the current fiscal year.
In other news, CFO Joshua L. Smiley sold 3,000 shares of the business’s stock in a transaction on Friday, March 16th. The shares were sold at an average price of $79.20, for a total transaction of $237,600.00. Following the completion of the transaction, the chief financial officer now directly owns 20,029 shares in the company, valued at approximately $1,586,296.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Donald A. Zakrowski sold 860 shares of Eli Lilly and stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $76.50, for a total transaction of $65,790.00. The disclosure for this sale can be found here. Insiders have sold a total of 15,261 shares of company stock valued at $1,225,085 over the last 90 days. Company insiders own 0.11% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “HBK Sorce Advisory LLC Acquires 6,840 Shares of Eli Lilly and Co (NYSE:LLY)” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/08/eli-lilly-and-co-lly-shares-bought-by-hbk-sorce-advisory-llc.html.
Eli Lilly and Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.